Literature DB >> 8384452

Soluble tumor necrosis factor receptors in human inflammatory synovial fluids.

P Roux-Lombard1, L Punzi, F Hasler, S Bas, S Todesco, H Gallati, P A Guerne, J M Dayer.   

Abstract

OBJECTIVE: To test synovial fluid (SF) for the presence of soluble fragments originating from distinct tumor necrosis factor receptors (TNF-sR55 and TNF-sR75) which bind to TNF and inhibit its biologic activity.
METHODS: TNF-sR55 and TNF-sR75 were measured in 62 SF samples by specific immunoassays using monoclonal antibodies.
RESULTS: Both TNF-sR were present in all of the SF tested. Their concentrations were higher in SF from patients with seropositive rheumatoid arthritis than in patients with other inflammatory arthritides. The relative amount of TNF-sR75, as compared with TNF-sR55, was higher in seropositive RA SF than in other SF.
CONCLUSION: The balance between TNF and its specific inhibitors may be critical to the biologic outcome mediated by this cytokine.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8384452     DOI: 10.1002/art.1780360408

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  21 in total

1.  Tumor necrosis factor (TNF) and TNFR1 polymorphisms are not risk factors for rheumatoid arthritis in a Mexican population.

Authors:  Daniel Cadena-Sandoval; Isidro Alemán-Ávila; Rosa Elda Barbosa-Cobos; Lizbeth Teresa Becerril-Mendoza; José Manuel Fragoso; Julián Ramírez-Bello
Journal:  Mol Biol Rep       Date:  2018-02-05       Impact factor: 2.316

2.  Soluble tumor necrosis factor alpha receptors in sera from leprosy patients.

Authors:  M E Munk; P Anding; A P Schettini; M G Cunha; S H Kaufmann
Journal:  Infect Immun       Date:  1999-01       Impact factor: 3.441

3.  [Evidence-based recommendations for the management of undifferentiated peripheral inflammatory arthritis (UPIA). The German perspective on the international 3e initiative].

Authors:  I H Tarner; K Albrecht; M Fleck; E Gromnica-Ihle; G Keyßer; L Köhler; I Kötter; K Krüger; J Kuipers; H Nüßlein; A Rubbert-Roth; J Wollenhaupt; M Schneider; B Manger; U Müller-Ladner
Journal:  Z Rheumatol       Date:  2014-05       Impact factor: 1.372

Review 4.  Etanercept: therapeutic use in patients with rheumatoid arthritis.

Authors:  L Garrison; N D McDonnell
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

5.  3rd International Symposium on the Immunotherapy of the Rheumatic Diseases. 10-14 May 1995, Cyprus. Abstracts.

Authors: 
Journal:  Ann Rheum Dis       Date:  1995-09       Impact factor: 19.103

Review 6.  Soluble receptors for cytokines and growth factors: generation and biological function.

Authors:  S Rose-John; P C Heinrich
Journal:  Biochem J       Date:  1994-06-01       Impact factor: 3.857

Review 7.  Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis.

Authors:  Christine R Culy; Gillian M Keating
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 8.  Etanercept: a review of its use in rheumatoid arthritis.

Authors:  B Jarvis; D Faulds
Journal:  Drugs       Date:  1999-06       Impact factor: 9.546

9.  A radioreceptor assay for TNF alpha-binding proteins.

Authors:  V Miller; K D Muirden
Journal:  Rheumatol Int       Date:  1994       Impact factor: 2.631

10.  Soluble intercellular adhesion molecule-1 and E-selectin levels in plasma of falciparum malaria patients and their lack of correlation with levels of tumor necrosis factor alpha, interleukin 1 alpha (IL-1 alpha), and IL-10.

Authors:  F Peyron; C Caux-Menetrier; P Roux-Lombard; T Niyongabo; P Aubry; P Deloron
Journal:  Clin Diagn Lab Immunol       Date:  1994-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.